These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 37438825)

  • 21. Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease.
    Kang JH; Vanderstichele H; Trojanowski JQ; Shaw LM
    Methods; 2012 Apr; 56(4):484-93. PubMed ID: 22503777
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Machine Learning Algorithm Helps Identify Non-Diagnosed Prodromal Alzheimer's Disease Patients in the General Population.
    Uspenskaya-Cadoz O; Alamuri C; Wang L; Yang M; Khinda S; Nigmatullina Y; Cao T; Kayal N; O'Keefe M; Rubel C
    J Prev Alzheimers Dis; 2019; 6(3):185-191. PubMed ID: 31062833
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Unlocking Preclinical Alzheimer's: A Multi-Year Label-Free In Vitro Raman Spectroscopy Study Empowered by Chemometrics.
    Lopez E; Etxebarria-Elezgarai J; García-Sebastián M; Altuna M; Ecay-Torres M; Estanga A; Tainta M; López C; Martínez-Lage P; Amigo JM; Seifert A
    Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731955
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer's disease.
    Gangishetti U; Christina Howell J; Perrin RJ; Louneva N; Watts KD; Kollhoff A; Grossman M; Wolk DA; Shaw LM; Morris JC; Trojanowski JQ; Fagan AM; Arnold SE; Hu WT
    Alzheimers Res Ther; 2018 Sep; 10(1):98. PubMed ID: 30253800
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Raman Spectroscopy to Diagnose Alzheimer's Disease and Dementia with Lewy Bodies in Blood.
    Paraskevaidi M; Morais CLM; Halliwell DE; Mann DMA; Allsop D; Martin-Hirsch PL; Martin FL
    ACS Chem Neurosci; 2018 Nov; 9(11):2786-2794. PubMed ID: 29865787
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Amyloid-β oligomers relate to cognitive decline in Alzheimer's disease.
    Jongbloed W; Bruggink KA; Kester MI; Visser PJ; Scheltens P; Blankenstein MA; Verbeek MM; Teunissen CE; Veerhuis R
    J Alzheimers Dis; 2015; 45(1):35-43. PubMed ID: 25547634
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness of the use of biomarkers in cerebrospinal fluid for Alzheimer's disease.
    Valcárcel-Nazco C; Perestelo-Pérez L; Molinuevo JL; Mar J; Castilla I; Serrano-Aguilar P
    J Alzheimers Dis; 2014; 42(3):777-88. PubMed ID: 24916543
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The combination of apolipoprotein E4, age and Alzheimer's Disease Assessment Scale - Cognitive Subscale improves the prediction of amyloid positron emission tomography status in clinically diagnosed mild cognitive impairment.
    Ba M; Ng KP; Gao X; Kong M; Guan L; Yu L;
    Eur J Neurol; 2019 May; 26(5):733-e53. PubMed ID: 30561868
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Raman Spectrometric Detection Methods for Early and Non-Invasive Diagnosis of Alzheimer's Disease.
    Huang CC; Isidoro C
    J Alzheimers Dis; 2017; 57(4):1145-1156. PubMed ID: 28304304
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multielectrode array analysis of cerebrospinal fluid in Alzheimer's disease versus mild cognitive impairment: a potential diagnostic and treatment biomarker.
    Görtz P; Siebler M; Ihl R; Henning U; Luckhaus C; Supprian T; Lange-Asschenfeldt C
    Biochem Biophys Res Commun; 2013 May; 434(2):293-7. PubMed ID: 23541573
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alzheimer's Disease Assessment Scale-Cognitive subscale variants in mild cognitive impairment and mild Alzheimer's disease: change over time and the effect of enrichment strategies.
    Podhorna J; Krahnke T; Shear M; Harrison JE;
    Alzheimers Res Ther; 2016 Feb; 8():8. PubMed ID: 26868820
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interactions between amyloid-β and tau in cerebrospinal fluid of people with mild cognitive impairment and Alzheimer's disease.
    Kristofikova Z; Ricny J; Kolarova M; Vyhnalek M; Hort J; Laczo J; Sirova J; Ripova D
    J Alzheimers Dis; 2014; 42 Suppl 3():S91-8. PubMed ID: 24670397
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Towards development of a novel screening method for identifying Alzheimer's disease risk: Raman spectroscopy of blood serum and machine learning.
    Ralbovsky NM; Fitzgerald GS; McNay EC; Lednev IK
    Spectrochim Acta A Mol Biomol Spectrosc; 2021 Jun; 254():119603. PubMed ID: 33743309
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Testing the 2018 NIA-AA research framework in a retrospective large cohort of patients with cognitive impairment: from biological biomarkers to clinical syndromes.
    Carandini T; Arighi A; Sacchi L; Fumagalli GG; Pietroboni AM; Ghezzi L; Colombi A; Scarioni M; Fenoglio C; De Riz MA; Marotta G; Scarpini E; Galimberti D
    Alzheimers Res Ther; 2019 Oct; 11(1):84. PubMed ID: 31615545
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diagnostic Impact of Cerebrospinal Fluid Biomarker (Pre-)Analytical Variability in Alzheimer's Disease.
    Niemantsverdriet E; Goossens J; Struyfs H; Martin JJ; Goeman J; De Deyn PP; Vanderstichele H; Engelborghs S
    J Alzheimers Dis; 2016; 51(1):97-106. PubMed ID: 26836187
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer's Disease Using Cerebrospinal Fluid Biomarkers in the AIBL Study.
    Burnham SC; Coloma PM; Li QX; Collins S; Savage G; Laws S; Doecke J; Maruff P; Martins RN; Ames D; Rowe CC; Masters CL; Villemagne VL
    J Prev Alzheimers Dis; 2019; 6(4):248-255. PubMed ID: 31686097
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Plasma d-glutamate levels for detecting mild cognitive impairment and Alzheimer's disease: Machine learning approaches.
    Chang CH; Lin CH; Liu CY; Huang CS; Chen SJ; Lin WC; Yang HT; Lane HY
    J Psychopharmacol; 2021 Mar; 35(3):265-272. PubMed ID: 33586518
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Longitudinal Study of Total and Phosphorylated α-Synuclein with Other Biomarkers in Cerebrospinal Fluid of Alzheimer's Disease and Mild Cognitive Impairment.
    Wang H; Stewart T; Toledo JB; Ginghina C; Tang L; Atik A; Aro P; Shaw LM; Trojanowski JQ; Galasko DR; Edland S; Jensen PH; Shi M; Zhang J;
    J Alzheimers Dis; 2018; 61(4):1541-1553. PubMed ID: 29376878
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Raman spectroscopy of blood serum for Alzheimer's disease diagnostics: specificity relative to other types of dementia.
    Ryzhikova E; Kazakov O; Halamkova L; Celmins D; Malone P; Molho E; Zimmerman EA; Lednev IK
    J Biophotonics; 2015 Jul; 8(7):584-96. PubMed ID: 25256347
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.